The American Society of Clinical Oncology is underway in Chicago and the high profile, annual cancer conference is producing its usual combination of scientific and financial excitement.
As cancer experts meet each year to discuss the latest research in treatment of the disease, Wall Street analysts, investors and the financial news media alike pay close attention to what may make or break a stock, never mind a whole company, given the vast amount of money and time spent on R&D.
Here's a round up of the movers and shakers at the ASCO conference Monday.
Onyx Pharmaceuticals may be the big story this year, having reported positive results in the treatment of liver cancer, a relatively rare but particularly brutal form of the disease. Genentech -- often a headline generator at the event -- remained optimistic about the future of Avastin despite a study that found smaller doses of the drug were just as effective as larger doses. Celgene said most patients responded positively to Revlimid, a drug used to treat multiple myeloma. ImClone Systems said Erbitux slowed the development of colon cancer.